A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRID
V116 elicits robust immune responses and is well tolerated in adults 18-64 years of age with conditions associated with an increased risk of PD.
Authors
- Michael D. Nissen (ORCID: https://orcid.org/0000-0003-1686-3313)
- Heather Platt (ORCID: https://orcid.org/0000-0002-0910-6077)
- Ulrike K. Buchwald (ORCID: https://orcid.org/0000-0002-6671-0115)
- Richard Tytus (ORCID: https://orcid.org/0000-0001-8247-8523)
- Amy Falk Russell
- Akira Kato (ORCID: https://orcid.org/0000-0002-2696-5703)
- Jayani Pathirana (ORCID: https://orcid.org/0000-0001-9678-4759)
- Nigel Gilchrist (ORCID: https://orcid.org/0009-0003-8907-8129)
- Hisao Kanou
- Kwang Ha Yoo (ORCID: https://orcid.org/0000-0001-9969-2657)
- Grzegorz Kania
- Paul T. Scott (ORCID: https://orcid.org/0000-0002-2348-4541)
- Doreen Fernsler
- Jianing Li (ORCID: https://orcid.org/0000-0002-0143-8894)
- Muhammad Waleed (ORCID: https://orcid.org/0000-0001-9770-6293)
- Carlos M. Pérez
Institutions
- Medical University of Lublin (PL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Royal Brisbane and Women's Hospital (AU)
- San Sebastián University (CL)
- Konkuk University Medical Center (KR)
- Kurume University Medical Center (JP)
- Shimonoseki City Hospital (JP)
- Prince Charles Hospital (AU)
- Christchurch Clinical Studies Trust (NZ)
- McMaster University (CA)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1093/cid/ciaf604
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00